Tick salivary gland as potential natural source for the discovery of promising antitumor drug candidates

Autor(es)

Chudzinski-Tavassi, Ana Marisa ^[1] ; Morais, Katia L. P. ^{[1, 2]} ; Fernandes Pacheco, Mario Thiego ^[1] ; Mesquita Pasqualoto, Kerly Fernanda ^[1] ; de Souza, Jean Gabriel ^{[1, 2]}

Afiliação do(s) autor(es)

^[1] Butantan Inst, Biochem & Biophys Lab, BR-05503900 Sao Paulo, SP - Brazil

^[2] Univ Fed Sao Paulo, Dept Biochem, Sao Paulo, SP - Brazil

• Tipo de documento: Artigo de Revisão
• Fonte: BIOMEDICINE & PHARMACOTHERAPY; v. 77, p. 14-19, FEB 2016.
• Citações Web of Science: 8

Resumo

Nowadays, the relationship between cancer blood coagulation is well established. Regarding biodiversity and bioprospection, the tick biology has become quite attractive natural source for coagulation inhibitors, since its saliva has a very rich variety of bioactive molecules. For instance, a Kunitz-type FXa inhibitor, named Amblyomin-X, was found through transcriptome of the salivary gland of the Amblyomma cajennense. tick. This TFPI-like inhibitor, after obtained as recombinant protein, has presented anticoagulant, antigionenic, and antitumor properties. Although its effects on blood coagulation could be relevant for antitumor effect, Amblyomin-X acts by non-hemostatic mechanisms, such as proteasome inhibition and autophagy inhibition. Notably, cytotoxicity was not observed on non-tumor cells treated with this protein, suggesting some selectivity for tumor cells. Considering the current efforts in order to develop effective anticancer therapies, the findings presented in this review strongly suggest Amblyomin-X as a promising novel antitumor drug candidate. (C) 2015 Elsevier Masson SAS. All rights reserved. (AU)

• Processo FAPESP: 13/07467-1 - CeTICS - Centro de Toxinas, Imuno-Resposta e Sinalização Celular
• Beneficiário: Hugo Aguirre Armelin
• Modalidade de apoio: Auxílio à Pesquisa - Centros de Pesquisa, Inovação e Difusão - CEPIDs
• Processo FAPESP: 10/52669-3 - Avaliação do mecanismo de ação pró-apoptótica do Amblyomin-X
• Beneficiário: Ana Marisa Chudzinski-Tavassi
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 11/05969-4 - Estudo do papel da dineína no mecanismo de ação antitumoral do Amblyomin-X em células de melanoma e adenocarcinoma de pâncreas
• Beneficiário: Mario Thiego Fernandes Pacheco
• Modalidade de apoio: Bolsas no Brasil - Doutorado Direto
• Processo FAPESP: 98/14307-9 - Center for Applied Toxinology
• Beneficiário: Hugo Aguirre Armelin
• Modalidade de apoio: Auxílio à Pesquisa - Centros de Pesquisa, Inovação e Difusão - CEPIDs
• Processo FAPESP: 10/07958-7 - Avaliação do mecanismo de ação pró-apoptótica do amblyomin-x
• Beneficiário: Kátia Luciano Pereira Morais
• Modalidade de apoio: Bolsas no Brasil - Doutorado